News

Cannabis-based experimental therapies currently under research, in particular Epidiolex, show significant promise to treat therapy-resistant epilepsy, including Dravet syndrome, according to a recent review. The report “Investigational cannabinoids in seizure disorders, what have we learned thus…

Tilray Canada has launched its newest product, Tilray 2:100, a formulation of therapeutic cannabis oil containing a high concentration of cannabidiol (CBD), which may help treat Canadian patients with conditions like Dravet syndrome. “We are excited to offer this highly concentrated CBD product to patients in Canada. We…

Researchers have identified two significant factors that can help predict cognitive outcomes in Dravet syndrome patients: Longer  treatment with antiepileptics that block sodium channels, and being younger when the first afebrile seizure occurs. The study “Influence of contraindicated…